Homology Medicines to Participate in Upcoming Investor Conferences
November 03 2021 - 8:28AM
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic
medicines company, announced today participation in the following
virtual conferences:
- Credit Suisse 30th Annual Healthcare Conference: Company
presentation on November 8 at 10:30 a.m. ET
- Stifel 2021 Healthcare Conference: Fireside chat on November 17
at 9:20 a.m. ET
The webcast presentations will be accessible on Homology’s
website in the Investors section, and the webcast replays will be
available on the website for 90 days following the
presentations.
About Homology Medicines, Inc.Homology
Medicines, Inc. is a clinical-stage genetic medicines company
dedicated to transforming the lives of patients suffering from rare
diseases by addressing the underlying cause of the disease. The
Company’s clinical programs include HMI-102, an investigational
gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene
editing candidate for PKU; and HMI-203, an investigational gene
therapy for Hunter syndrome. Additional programs focus on
metachromatic leukodystrophy (MLD), paroxysmal nocturnal
hemoglobinuria (PNH) and other diseases. Homology’s proprietary
platform is designed to utilize its family of 15 human
hematopoietic stem cell-derived adeno-associated virus vectors
(AAVHSCs) to precisely and efficiently deliver genetic medicines in
vivo through a gene therapy or nuclease-free gene editing modality,
as well as to deliver one-time gene therapy to produce antibodies
throughout the body through the GTx-mAb platform. Homology has a
management team with a successful track record of discovering,
developing and commercializing therapeutics with a focus on rare
diseases. Homology believes its initial clinical data and
compelling preclinical data, scientific and product development
expertise, internal manufacturing capabilities and broad
intellectual property position the Company as a leader in genetic
medicines. For more information, visit
www.homologymedicines.com.
Company ContactsTheresa McNeelyChief
Communications Officer and Patient
Advocatetmcneely@homologymedicines.com781-301-7277
Media Contact:Cara Mayfield Vice President,
Patient Advocacy and Corporate Communications
cmayfield@homologymedicines.com 781-691-3510
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Apr 2023 to Apr 2024